Apixaban: all 180 studies that test it
Page 2 of 2. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)Active, not recruitingNCT07853612Phase 4
- Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary EmbolismCompletedNCT07774273Not applicable
- Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser AblationCompletedNCT07699796Phase 4
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy ParticipantsCompletedNCT07312851Phase 1
- Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet DrugsCompletedNCT06933056Early Phase 1
- Bioequivalence Study of Apixaban 5 mg Film-Coated TabletCompletedNCT06817811Phase 1
- Dabigatran Versus Apixaban in Cerebral Venous ThrombosisStatus unknownNCT06551415Phase 3
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)Active, not recruitingNCT06449469Not applicable
- Single Dose Trial of VMX-C001 in Healthy Subjects With and Without FXa Direct Oral AnticoagulantCompletedNCT06372483Phase 1
- Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human SubjectsCompletedNCT06043297Phase 1
- Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy VolunteersCompletedNCT05995119Early Phase 1
- PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy VolunteersCompletedNCT05723510Phase 1
- Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants SubjectsStatus unknownNCT05491460Phase 1
- Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal DisconnectionCompletedNCT05304455Not applicable
- Apixaban in Patients With Left Ventricular ThrombusCompletedNCT05208398Phase 3
- Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical CareStatus unknownNCT05088928Phase 2
- AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve ImplantationCompletedNCT05035277Phase 3
- Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial HemorrhageStatus unknownNCT04891861Phase 3
- Causes and Prevention of Thromboembolic Disease in Nephrotic SyndromeCompletedNCT04850378Phase 1/2
- HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)Status unknownNCT04801940Phase 3
- Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19TerminatedNCT04746339Phase 4
- Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF TrialStatus unknownNCT04696120Phase 2
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）CompletedNCT04645550Phase 4
- FREEDOM COVID-19 Anticoagulation StrategyCompletedNCT04512079Phase 4
- Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular AccessStatus unknownNCT04489849Phase 4
- Efficacy of Apixaban in Malignancy With Deep Venous ThrombosisStatus unknownNCT04462003Phase 3
- A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic SyndromeCompletedNCT04278729Phase 1
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
- Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.Status unknownNCT04229264Phase 3
- Pharmacokinetics of Apixaban in Patients Undergoing PancreaticoduodenectomyCompletedNCT04191928Phase 1
- A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)Status unknownNCT04128254Phase 4
- Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDsTerminatedNCT04106700Phase 2
- Oral Anticoagulant Apixaban for Treatment of Venous ThromboembolismCompletedNCT04041843Phase 2
- Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant RecipientsCompletedNCT04023760Phase 4
- Apixaban for Intrahepatic Non Cirrhotic Portal HypertensionActive, not recruitingNCT04007289Phase 3
- DOAC Versus VKA After Cardiac SurgeryWithdrawnNCT04002011Phase 2
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial FibrillationCompletedNCT03996772Phase 3
- API-CAT STUDY for APIxaban Cancer Associated ThrombosisCompletedNCT03692065Phase 3
- Apixaban for Extended Anticoagulation (APIDULCIS)TerminatedNCT03678506Phase 4
- Apixaban in End-stage Kidney Disease : A Pharmacokinetics StudyCompletedNCT03456648Phase 2
- Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord InjuryTerminatedNCT03200613Phase 2
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral AnticoagulantsCompletedNCT03181386Phase 3
- Start or STop Anticoagulants Randomised Trial (SoSTART)CompletedNCT03153150Phase 3
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous ThromboembolismStatus unknownNCT03139487Phase 2
- Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under ApixabanTerminatedNCT03136510Not applicable
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Active, not recruitingNCT03129555Phase 4
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationActive, not recruitingNCT03129490Phase 4
- Drug Interaction Study of Apixaban With Cyclosporine and TacrolimusCompletedNCT03083782Phase 1
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedNCT03083704Phase 1
- Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary EmbolismStatus unknownNCT02946944Phase 1
- Apixaban for Routine Management of Upper Extremity Deep Venous ThrombosisTerminatedNCT02945280Phase 4
- ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)CompletedNCT02935855Phase 4
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)CompletedNCT02933697Phase 3
- Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsCompletedNCT02912234Phase 1
- Apixaban in HemodialysisCompletedNCT02672709Phase 4
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial FibrillationStatus unknownNCT02666157Phase 4
- Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic StenosisCompletedNCT02664649Phase 3
- Venous Thromboembolism in Renally Impaired Patients and Direct Oral AnticoagulantsTerminatedNCT02664155Phase 3
- Pharmacokinetics of Apixaban in Nephrotic SyndromeCompletedNCT02599532Phase 1
- Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP StudyCompletedNCT02581176Phase 4
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial FibrillationCompletedNCT02565693Phase 2
- Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot StudyWithdrawnNCT02450682Phase 2
- Apixaban for Treatment of Embolic Stroke of Undetermined SourceCompletedNCT02427126Phase 3
- Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical EmboliWithdrawnNCT02378623Phase 2
- Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid SyndromeCompletedNCT02295475Phase 4
- Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy SubjectsCompletedNCT02262533Phase 1
- Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy SubjectsCompletedNCT02262520Phase 1
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist TherapyCompletedNCT02227550Phase 4
- Triple vs. Dual TherapyCompletedNCT02080858Phase 1
- Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDsCompletedNCT02066454Phase 3
- Apixaban for the Prevention of Venous Thromboembolism in Cancer PatientsCompletedNCT02048865Phase 2
- Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial FibrillationCompletedNCT01938248Phase 4
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular EventsStatus unknownNCT01924325Phase 2/3
- Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic DisorderCompletedNCT01707394Phase 1
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic EventsCompletedNCT01675076Phase 3
- Food Effect Study For Apixaban Commercial Image TabletsCompletedNCT01437839Phase 1
- Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous CatheterTerminatedNCT01195727Phase 1
- Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy VolunteersCompletedNCT00914641Phase 1
- Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT StudyCompletedNCT00252005Phase 2
- BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryCompletedNCT00097357Phase 2/3